$SBFM is like a $4.5m market cap with $9.3m in q2 sales. what am i missing here?
SBFM looks kinda weird on paper
q2 sales were about $9.26m and they had roughly $13.75m cash at june 30 while the whole company is sitting around a $4.5m market cap
obviously that doesnt automatically mean its cheap lol
theyre still losing money and dilution is the obvious thing to watch. operating loss was about $1.61m though vs $2.05m last year
the actual pharma side has 60 generic prescription drugs on the market in Canada and theyve started shipping amoxicillin. dienogest also got Canadian approval with shipments expected later this year
so what exactly is the market pricing in here?
are the losses and dilution risk enough to justify the valuation or is SBFM just getting ignored because its another tiny biotech name?